Aerie Pharmaceuticals, Inc.

Good afternoon, thank you for standing by, and welcome to the AIRI Pharmaceuticals 3rd Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. Today's conference call will be recorded. It is now my pleasure to turn the floor over to AIRI's General Counsel, John LaRocca. Please go ahead, sir.

Thank you, Chris. Good afternoon, and thank you for joining us. With us today are Ben McGraw, ARIES Interim Executive Chairman, Tom Mitro, ARIES President and Chief Operating Officer, David Hollander, ARIES Chief Research and Development Officer, Casey Kopchinsky, ARIES Chief Scientific Officer, and Jeff Calabrese, ARIES Vice President of Finance and Principal Accounting Officer. Today's call is also being webcast live on our website, investors.arifarma.com. and it will be available for replay as indicated in our press release. Now for forward-looking statements and non-GAAP financial measures. On this call, we will make certain forward-looking statements, including statements, forecasts, and observations regarding our future financial and operating performance and impacts of the COVID-19 pandemic, including our observations regarding ongoing operating expenses and net revenue per bottle. These statements will include observations associated with our commercialization of Repressa and Roquitane in the United States, our collaboration in Japan, and prospects for potential collaboration in Europe. They will also include plans and expectations regarding the success, timing, and cost of our clinical trials. Additionally, we will discuss progress regarding maintaining, requesting, or obtaining approvals from regulatory agencies of our products, product candidates, and implants, along with the associated business strategies regarding these products, product candidates, and implants. Finally, we will address our financial liquidity and other statements related to future events. These statements are based on the beliefs and expectations of management as of today. Our actual results may differ materially from our expectations. Investors should carefully read the risks and uncertainties described in today's press release as well as the risk factors included in our filings with the SEC. We assume no obligation to revise or update forward-looking statements, whether as the result of new information, future events, or otherwise. Please note that we expect to file our 10Q tomorrow. In addition, during this call, we will be discussing certain adjusted or non-GAAP financial measures. For additional disclosures relating to these non-GAAP financial measures, including a reconciliation to the most directly comparable GAAP measures, please see today's press release, which is posted on the Investor Relations section of our website. With that, I will turn the call over to Ben.

Thanks, John. Good afternoon to everyone. Thanks for joining us today. We had a very good quarter, and we have a number of specific items to address today. These include our third quarter results, continued progress with our growing pipeline, and additional perspective on our global strategy. I want to begin by making five very important points. First, we have good commercial performance. You'll hear that in Tom Mitro's reporting of the results for the quarter. Our two commercial products are gaining market share and are consistently hitting analysts' revenue projections. Second, we are leveraging our products via ex-U.S. partnerships. It's our expectation these partnerships will enhance our balance sheet and I'll provide further comment on that one. Third, we have two clearly differentiated Phase III ready products in development and a strong pipeline behind them. You'll hear that from David Hollander. Fourth, we have a well-functioning manufacturing operation in Athlon, Ireland, and I'll comment on that. Fifth, we're in a good financial position, and Jeff Calabrese will cover that. I know some of you are concerned about the two departures from our senior management team. The management team we have is strong, and we're making good progress and filling those vacancies. As we've previously reported, we have a search open for a CEO, and we're now interviewing well-qualified candidates. The board takes its fiduciary responsibility very seriously and will take the time necessary to find the person best suited to execute the responsibilities of the job. In addition, we have an active search for a CFO, and we are interviewing very good candidates for that position right now. Now I'll turn the call over to Tom to provide an update on the U.S. glaucoma franchise, after which David will provide an update on the pipeline. I'll address our global activities, and Jeff Calabrese will wrap up with the financials. Okay, Tom.